Jan Zedenius

List of Publications by Year
in descending order

72	1,790	304743 22	302126 39
papers	citations	h-index	g-index

72	72	72	2283
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Nuclear-specific accumulation of telomerase reverse transcriptase (TERT) mRNA in TERT promoter mutated follicular thyroid tumours visualised by in situ hybridisation: a possible clinical screening tool?. Journal of Clinical Pathology, 2022, 75, 658-662.	2.0	5
2	Synchronous lateral lymph node metastases from papillary and follicular thyroid carcinoma: case report and review of the literature. Thyroid Research, 2022, 15, 1.	1.5	7
3	Prognostic Utility of the Ki-67 Labeling Index in Follicular Thyroid Tumors: a 20-Year Experience from a Tertiary Thyroid Center. Endocrine Pathology, 2022, 33, 231-242.	9.0	12
4	Synergistic effects of telomerase reverse transcriptase and regulator of telomere elongation helicase 1 on aggressiveness and outcomes in adrenocortical carcinoma. Biomedicine and Pharmacotherapy, 2022, 149, 112796.	5.6	7
5	Cytoâ€morphological features of parathyroid lesions: Fineâ€needle aspiration cytology series from an endocrine tumor referral center. Diagnostic Cytopathology, 2022, 50, 75-83.	1.0	6
6	Metastatic Neuroendocrine Neoplasms of Unknown Primary: Clues from Pathology Workup. Cancers, 2022, 14, 2210.	3.7	7
7	A single parathyroid hormone measurement two hours after a thyroidectomy reliably predicts permanent hypoparathyroidism. Scandinavian Journal of Surgery, 2021, 110, 322-328.	2.6	6
8	Perithyroidal Salivary Gland Acinic Cell Carcinoma: Morphological and Molecular Attributes of a Unique Lesion. Head and Neck Pathology, 2021, 15, 628-637.	2.6	1
9	Macrofollicular Variant of Follicular Thyroid Carcinoma (MV-FTC) with a Somatic DICER1 Gene Mutation: Case Report and Review of the Literature. Head and Neck Pathology, 2021, 15, 668-675.	2.6	3
10	Spatial Distribution Patterns of Clinically Relevant TERT Promoter Mutations in Follicular Thyroid Tumors of Uncertain Malignant Potential. Journal of Molecular Diagnostics, 2021, 23, 212-222.	2.8	12
11	TERT promoter mutations in primary and secondary WHO grade III meningioma. Brain Pathology, 2021, 31, 61-69.	4.1	27
12	The Clinical Significance of Lymph Node Ratio and Kiâ€67 Expression in Papillary Thyroid Cancer. World Journal of Surgery, 2021, 45, 2155-2164.	1.6	17
13	Pan-genomic characterization of high-risk pediatric papillary thyroid carcinoma. Endocrine-Related Cancer, 2021, 28, 337-351.	3.1	11
14	Institutional characterisation of water clear cell parathyroid adenoma: a rare entity often unrecognised by TC-99m-sestamibi scintigraphy. Pathology, 2021, 53, 852-859.	0.6	6
15	Metastasis to the thyroid gland: Characterization and survival of an institutional series spanning 28 years. European Journal of Surgical Oncology, 2021, 47, 1364-1369.	1.0	15
16	Whole-genome Sequencing of Follicular Thyroid Carcinomas Reveal Recurrent Mutations in MicroRNA Processing Subunit DGCR8. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3265-3282.	3.6	17
17	Parathyroid Adenoma With Respiratory-Like Epithelium: Case Report of a Potential Mimic With Unknown Etiology. Frontiers in Endocrinology, 2021, 12, 724766.	3.5	0
18	Macrofollicular variant follicular thyroid tumors are DICER1 mutated and exhibit distinct histological features. Histopathology, 2021, 79, 661-666.	2.9	28

#	Article	IF	Citations
19	Development of metastatic poorly differentiated thyroid cancer from a sub-centimeter papillary thyroid carcinoma in a young patient with a germline MET mutation â€“ association or random chance?. Thyroid Research, 2021, 14, 19.	1.5	0
20	TERT Promoter Mutated Follicular Thyroid Carcinomas Exhibit a Distinct microRNA Expressional Profile with Potential Implications for Tumor Progression. Endocrine Pathology, 2021, 32, 513-516.	9.0	5
21	Pan-Genomic Sequencing Reveals Actionable CDKN2A/2B Deletions and Kataegis in Anaplastic Thyroid Carcinoma. Cancers, 2021, 13, 6340.	3.7	18
22	Wholeâ€genome sequencing of synchronous thyroid carcinomas identifies aberrant DNA repair in thyroid cancer dedifferentiation. Journal of Pathology, 2020, 250, 183-194.	4.5	40
23	Invited Commentary: Use of Electrical Impedance Spectroscopy for Intraoperative Tissue Differentiation During Thyroid and Parathyroid Surgery. World Journal of Surgery, 2020, 44, 486-487.	1.6	1
24	Sarcoma of the breast: breast cancer history as etiologic and prognostic factorâ€”A population-based caseâ€“control study. Breast Cancer Research and Treatment, 2020, 183, 669-675.	2.5	11
25	Clinical Routine Application of the Second-generation Neuroendocrine Markers ISL1, INSM1, and Secretagogin in Neuroendocrine Neoplasia: Staining Outcomes and Potential Clues for Determining Tumor Origin. Endocrine Pathology, 2020, 31, 401-410.	9.0	35
26	Lipoadenoma of the Parathyroid Gland: Characterization of an Institutional Series Spanning 28ÂYears. Endocrine Pathology, 2020, 31, 156-165.	9.0	13
27	Metastatic Anaplastic Thyroid Carcinoma in Complete Remission: Morphological, Molecular, and Clinical Work-Up of a Rare Case. Endocrine Pathology, 2020, 31, 77-83.	9.0	7
28	Metastatic malignant melanoma with neuroendocrine differentiation: a case report and review of the literature. Journal of Medical Case Reports, 2020, 14, 44.	0.8	8
29	GABPA-dependent down-regulation of DICER1 in follicular thyroid tumours. Endocrine-Related Cancer, 2020, 27, 295-308.	3.1	22
30	Proteomics identifies neddylation as a potential therapy target in small intestinal neuroendocrine tumors. Oncogene, 2019, 38, 6881-6897.	5.9	7
31	Telomerase activation in small intestinal neuroendocrine tumours is associated with aberrant TERT promoter methylation, but not hot-spot mutations. Epigenetics, 2019, 14, 1224-1233.	2.7	4
32	Signet ring cell variant of follicular thyroid carcinoma: Report of two cases with focus on morphological, expressional and genetic characteristics. Diagnostic Pathology, 2019, 14, 127.	2.0	3
33	Clinical Routine TERT Promoter Mutational Screening of Follicular Thyroid Tumors of Uncertain Malignant Potential (FT-UMPs): A Useful Predictor of Metastatic Disease. Cancers, 2019, 11, 1443.	3.7	31
34	Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up. Surgery, 2019, 166, 901-906.	1.9	12
35	TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up. Endocrine Pathology, 2019, 30, 246-248.	9.0	20
36	Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior. American Journal of Surgical Pathology, 2019, 43, 409-421.	3.7	24

#	Article	IF	Citations
37	The Value of Histological Algorithms to Predict the Malignancy Potential of Pheochromocytomas and Abdominal Paragangliomasâ€"A Meta-Analysis and Systematic Review of the Literature. Cancers, 2019, 11, 225.	3.7	52
38	Synchronous aldosterone- and cortisol-producing adrenocortical adenomas diagnosed using CYP11B immunohistochemistry. SAGE Open Medical Case Reports, 2019, 7, 2050313X1988377.	0.3	5
39	TERT aberrancies: a screening tool for malignancy in follicular thyroid tumours. Endocrine-Related Cancer, 2018, 25, 723-733.	3.1	42
40	Telomerase reverse transcriptase promoter hypermethylation is associated with metastatic disease in abdominal paraganglioma. Clinical Endocrinology, 2018, 88, 343-345.	2.4	12
41	TERT Immunohistochemistry Is a Poor Predictor of TERT Promoter Mutations and Gene Expression in Follicular Thyroid Carcinoma. Endocrine Pathology, 2018, 29, 380-383.	9.0	16
42	Over-diagnosis of potential malignant behavior in MEN 2A-associated pheochromocytomas using the PASS and GAPP algorithms. Langenbeck's Archives of Surgery, 2018, 403, 785-790.	1.9	17
43	Papillary thyroid carcinoma with pleomorphic tumor giant cells in a pregnant woman â€" a case report. BMC Endocrine Disorders, 2018, 18, 46.	2.2	7
44	TERT promoter mutational screening as a tool to predict malignant behaviour in follicular thyroid tumoursâ€"three examples from the clinical routine. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 639-643.	2.8	14
45	High Ki-67 index in fine needle aspiration cytology of follicular thyroid tumors is associated with increased risk of carcinoma. Endocrine, 2018, 61, 293-302.	2.3	17
46	Regional differences in somatostatin receptor 2 (SSTR2) immunoreactivity is coupled to level of bowel invasion in small intestinal neuroendocrine tumors. Neuroendocrinology Letters, 2018, 39, 305-309.	0.2	4
47	Primary hyperparathyroidism, hypercalciuria, and bone recovery after parathyroidectomy. Surgery, 2017, 162, 429-436.	1.9	25
48	Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma. Oncotarget, 2016, 7, 21332-21346.	1.8	37
49	Proteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3616-3627.	3.6	10
50	Minimally invasive follicular thyroid carcinomas: prognostic factors. Endocrine, 2016, 53, 505-511.	2.3	21
51	FGF23, metabolic risk factors, andÂblood pressure in patients withÂprimary hyperparathyroidism undergoing parathyroid adenomectomy. Surgery, 2016, 159, 211-217.	1.9	17
52	Secretome protein signature of human gastrointestinal stromal tumor cells. Experimental Cell Research, 2015, 336, 158-170.	2.6	6
53	Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Human Molecular Genetics, 2015, 24, 2318-2329.	2.9	290
54	Differential Protein Expression Profiles of Cyst Fluid from Papillary Thyroid Carcinoma and Benign Thyroid Lesions. PLoS ONE, 2015, 10, e0126472.	2.5	22

#	Article	IF	Citations
55	Global hypomethylation and promoter methylation in small intestinal neuroendocrine tumors. Epigenetics, 2014, 9, 987-997.	2.7	50
56	Intracellular concentration of the tyrosine kinase inhibitor imatinib in gastrointestinal stromal tumor cells. Anti-Cancer Drugs, 2014, 25, 415-422.	1.4	13
57	Human Anaplastic Thyroid Carcinoma Cells Are Sensitive to NK Cellâ€“Mediated Lysis via ULBP2/5/6 and Chemoattract NK Cells. Clinical Cancer Research, 2014, 20, 5733-5744.	7.0	47
58	Functional role of the Ca2+-activated Clâ¯ channel DOG1/TMEM16A in gastrointestinal stromal tumor cells. Experimental Cell Research, 2014, 326, 315-325.	2.6	49
59	Evidence for Ca2+-regulated ATP release in gastrointestinal stromal tumors. Experimental Cell Research, 2013, 319, 1229-1238.	2.6	13
60	Is somatic RET mutation a prognostic factor for sporadic medullary thyroid carcinoma?. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 432-433.	2.8	8
61	Incidence and survival of Swedish patients with differentiated thyroid cancer. International Journal of Cancer, 2003, 106, 569-573.	5.1	71
62	Surgical Treatment of Hyperthyroidism: A Ten-Year Experience. Thyroid, 2001, 11, 187-192.	4.5	71
63	Gain of 1q and loss of 9q21.3-q32 are associated with a less favorable prognosis in papillary thyroid carcinoma. Genes Chromosomes and Cancer, 2001, 32, 43-49.	2.8	40
64	Loss of heterozygosity in sporadic parathyroid tumours: involvement of chromosome 1 and the MEN1 gene locus in 11q13.. Clinical Endocrinology, 2000, 53, 85-92.	2.4	34
65	Molecular Genetics of Thyroid Tumors and Surgical Decision-making. World Journal of Surgery, 2000, 24, 923-933.	1.6	43
66	MULTINODULAR GOITRE PRESENTING AS A CLINICAL SINGLE NODULE: HOW EFFECTIVE IS HEMITHYROIDECTOMY?. Australian and New Zealand Journal of Surgery, 1999, 69, 34-36.	0.2	40
67	Low frequency of numerical chromosomal aberrations in follicular thyroid tumors detected by comparative genomic hybridization. , 1999, 25, 349-353.		28
68	Sporadic follicular thyroid tumors show loss of a 200-kb region in 11q13 without evidence for mutations in theMEN1 gene. , 1999, 26, 35-39.		24
69	Low frequency of numerical chromosomal aberrations in follicular thyroid tumors detected by comparative genomic hybridization. Genes Chromosomes and Cancer, 1999, 25, 349-353.	2.8	1
70	Anaplastic Giant Cell Carcinoma of the Thyroid Gland: Treatment and Survival Over a 25â€Year Period. World Journal of Surgery, 1998, 22, 725-730.	1.6	113
71	Deletions of the long arm of chromosome 10 in progression of follicular thyroid tumors. Human Genetics, 1996, 97, 299-303.	3.8	51
72	Stromal Fibroblasts Adjacent to Invasive Thyroid Tumors: Expression of Gelatinase A But Not Stromelysin 3 mRNA. World Journal of Surgery, 1996, 20, 101-106.	1.6	32